Blood test may help predict which breast cancers will recur

December 8, 2017 by Marilynn Marchione
Blood test may help predict which breast cancers will recur
In this Tuesday, April 28, 2015 file photo, a patient has her blood drawn for a liquid biopsy at a hospital in Philadelphia. A study released on Friday, Dec. 8, 2017 found that a blood test five years after breast cancer treatment helped identify women who were likely to relapse, long before a lump or other signs appeared. (AP Photo/Jacqueline Larma)

A blood test five years after breast cancer treatment helped identify some women who were more likely to relapse, long before a lump or other signs appeared, a preliminary study found.

It was the largest experiment so far to use these tests, called liquid biopsies , for breast cancer. Results suggest they someday may help reveal which women need longer preventive therapy and which ones can be spared it.

"It could be providing an early warning sign" for some women that cancer is returning, said Dr. Joseph Sparano of Montefiore Einstein Center for Cancer Care in New York.

On the other hand, "if you had a negative test, there was a 98 percent chance you would not have a recurrence in the next two years" and perhaps could skip further treatment, he said.

Sparano led the study and gave results Friday at the San Antonio Breast Cancer Symposium.

The test—CellSearch, sold by Menarini-Silicon Biosystems—looks for stray cancer cells in the blood.

Breast cancer survivors may be tempted to rush out and get it, but doctors say it's too soon for that. Although it's been used for about a decade to monitor certain patients with advanced cancer during treatment, its value for helping to predict breast cancer relapse risk is not well established, and insurers won't pay the $600 to $900 tab.

The new study should spur more research on this right away, said Dr. Massimo Cristofanilli, a breast cancer specialist at Northwestern University in Chicago who has used these tests and consults for another company developing one.

"Clearly, to me, we have to do something" now that this study suggests a wider role for them, he said.

It involved 547 women in long-term follow-up from an earlier cancer drug study. Two-thirds of them had cancers fueled by estrogen, and in most cases it had spread to lymph nodes but not more widely.

All had surgery and chemotherapy followed by hormone-blocking medicines for five years. Guidelines now recommend considering hormone blockers for up to 10 years, but they have side effects and their benefit beyond five years is fairly small. So finding a way to tell who really needs that would be a big help.

Women in the study had a CellSearch test five years on average after their cancer was found and treated.

Among those with estrogen-fueled disease, 5 percent had cancer cells in the blood test, and they turned out to have a 22-fold higher risk of recurrence within roughly two years compared to women whose blood test was negative.

About 65 percent of women with hormone-positive disease and a positive blood test did not have a new breast cancer within two years, but that doesn't mean the blood test gave a false alarm, Sparano said.

"We haven't followed the patients long enough"—it could be that more tumors become evident with more time, he said.

The blood test seemed to do a good job of identifying which of these hormone-positive patients were at low risk of recurrence, suggesting that women who test negative may be able to forgo an additional five years of hormone-blocking medicines.

The test did not predict recurrence risk in the rest of the women in the study, whose tumors were not fueled by estrogen. They have a lower risk of recurrence after five years to start with.

The study was funded by the Breast Cancer Research Foundation, Susan G. Komen Foundation and the National Cancer Institute.

Explore further: Adjuvant Trastuzumab did not improve outcomes for patients with HER2-low breast cancer

Related Stories

Adjuvant Trastuzumab did not improve outcomes for patients with HER2-low breast cancer

December 6, 2017
Adding trastuzumab (Herceptin) to standard adjuvant chemotherapy did not improve invasive disease–free survival for patients with early-stage breast cancer found to have low levels of HER2, as defined as immunohistochemistry ...

Pregnancy poses no greater risk to breast cancer survivors

October 26, 2017
A recent study published in the Journal of the National Cancer Institute indicates that pregnancy does not incur a greater risk of relapse for survivors of breast cancer. The safety of pregnancy for women with history of ...

Circulating tumor cells associated with relapse in late-stage melanoma patients

November 7, 2017
A study revealing a connection between circulating tumor cells (CTCs) and relapse in stage IV melanoma patients points to liquid biopsy as a potential predictor of patients at high risk for disease progression. CTCs, tumor ...

Obese and overweight women face increased risk of recurrence of most common type of breast cancer

August 27, 2012
Extra pounds—even within the overweight but not obese range—are linked to a higher risk of recurrence of the most common type of breast cancer despite optimal cancer treatment, according to a new study published early ...

Team publishes initial data from TAILORx breast cancer trial

September 28, 2015
Initial results were announced today from the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, a multi-center prospectively conducted trial of more than 10,000 women with early stage breast cancer sponsored ...

Intermountain healthcare researchers launch major three-year genomics breast cancer study

October 11, 2017
Cancer researchers at Intermountain Medical Center and the Intermountain Precision Genomics Program in Salt Lake City are launching an exciting, new three-year study to determine if a blood test that looks for DNA from a ...

Recommended for you

Scientists block the siren call of two aggressive cancers

January 23, 2018
Aggressive cancers like glioblastoma and metastatic breast cancer have in common a siren call that beckons the bone marrow to send along whatever the tumors need to survive and thrive.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.